Enzo's Q2 Revenues Improve 5 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Monday a 5 percent increase year over year in fiscal second-quarter revenues.

For the three months ended Jan. 31, total revenues rose to $25.0 million from $23.7 million driven by growth in the company's Clinical Labs segment and an increase in royalty and licensing revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."